

---

## ABSTRACT OF THE DISCLOSURE

03 The invention relates to antibodies which bind to the CD23 (FC $\epsilon$ RII) type II molecule particularly altered antibodies including antibodies which bind to the CD23 (FC $\epsilon$ RII) type II molecule characterized by an affinity constant equal to or greater than  $1 \times 10^9$  Ka Mol $^{-1}$ , the preparation of such antibodies, pharmaceutical compositions which contain such antibodies and their use in therapy particularly in the treatment of autoimmune and inflammatory disorders.

---